Philip Kuruvilla

Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma

Danyal Ladha, Donna Reece, Guido Lancman, Arleigh McCurdy et autres

Abstract Introduction Regimens based on bortezomib and lenalidomide have been a mainstay of treatment for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) patients (pts). Recently, the phase 3 MAIA trial established DRd as the new standard of care (SoC), with a median …

ca (code pays fourni par la source)

Real-world outcomes of teclistamab for multiple myeloma in Canada: Multi-institutional report from the Canadian myeloma research group (CMRG) database

Guido Lancman, Donna Reece, Arleigh McCurdy, Engin Gul et autres

Abstract Introduction: Teclistamab is a highly effective treatment for relapsed multiple myeloma (MM), with an overall response rate (ORR) of 63% and progression-free survival (PFS) of 11.4 months in the MajesTEC-1 trial. real-world data are needed to understand outcomes in a broader …

ca, gb, us, jp, au (code pays fourni par la source)

Implementing standardized documentation for goals of care among advanced stage cancer patients.

William Raskin, Jennifer Umlauf, Patricia Mosnia, Parneet Cheema et autres

e23236 Background: Early goals of care (GOC) discussions are associated with better health outcomes and quality of life for patients with advanced cancer. We describe a quality improvement initiative to improve documentation of GOC discussions. Methods: Using a Plan-Do-Study-Act model, we promoted …

ca, us (code pays fourni par la source)

Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

Hira Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel et autres

Measurable/minimal residual disease (MRD) is 1 of the most powerful prognostic factors for progression-free survival and overall survival in multiple myeloma (MM) and may guide therapeutic approaches. Here, we provide an overview of the current state of MRD testing in MM in …

ca, us, gb (code pays fourni par la source)

Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report

Alina Rashid, Philip Kuruvilla

ca (code pays fourni par la source)

Is six weeks of antibiotic therapy sufficient for the management of spinal infections? Insights from the manchester experience

Gayatri Amirthalingam, Philip Kuruvilla, M. Dherijha, Shatha Saadi Mohammad

gb (code pays fourni par la source)

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Jeff P. Sharman, Jan A. Burger, Jacqueline C. Barrientos, Philip Kuruvilla et autres

Background: Ibrutinib is a first-in-class Bruton's tyrosine kinase inhibitor (BTKi) that has changed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) with durable responses and improved overall survival (OS). In the pivotal Phase 3 GLOW and Phase 2 CAPTIVATE trials, …

us, ca, it (code pays fourni par la source)

Real World Experience of Ibrutinib in an Ethnically Diverse Canadian Community Hospital

Philip Kuruvilla, Juhi Husain, Henry Jacob Conter, William To-Dang et autres

Chronic Lymphocytic Leukemia (CLL) is an indolent lymphoproliferative disorder commonly managed in community centers. Ibrutinib revolutionized the management of patients with CLL (2). Ibrutinib was initially considered an easy to administer, well tolerated oral medication with excellent efficacy. It was the first …

ca (code pays fourni par la source)

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy

Fatima Khadadah, Sonia Cerquozzi, Harold J. Olney, Christina Fraga et autres

ca (code pays fourni par la source)

Comments on: Sutureless, glueless pterygium surgery by Jipina et al.

Philip Kuruvilla

Dear Editor, The article by Jipna et al. in May–August 2022 edition of KJO about sutureless glueless pterygium surgery was useful and interesting. In India, any method to cut costs is most welcome, provided there is no compromise in quality. You have …

us (code pays fourni par la source)

Mitigating the risk of COVID-19 in a large community oncology clinic and its impact on the patient experience.

Ravnoor Kang, Rachel Dhir, Marco Iafolla, William Raskin et autres

e18631 Background: Cancer patients have a high risk of severe illness from COVID-19 infection, and the William Osler Health System oncology clinic (WOHS-OC) is in Brampton, ON, Canada, a COVID-19 hotspot with high community COVID-19 prevalence. As such, heightened symptom screening prior …

ca (code pays fourni par la source)

P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.

Fatima Khadadah, Anna Turkina, Elza Lomaia, Е. В. Морозова et autres

Background: Asciminib (ASC) is a novel, first in class ‘specifically targeting the ABL myristate pocket (STAMP) inhibitor. Recent update of the ASCEMBL phase 3 data showed a superior cumulative incidence of major molecular rate (MMR) of 33.2% with ASC over bosutinib (BOS) …

ca, ru (code pays fourni par la source)